Related Experiment Video
Updated: Apr 28, 2026
08:25
Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
2.4K
ABCA7 in Alzheimer's Disease
Qing-Fei Zhao1, Jin-Tai Yu, Meng-Shan Tan
1Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao, China.
Molecular Neurobiology
|June 1, 2014
Summary
The ATP-binding cassette A7 (ABCA7) gene is linked to late-onset Alzheimer's disease (LOAD). Increased ABCA7 levels in the brain correlate with Alzheimer's pathology, suggesting it as a therapeutic target.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- The ATP-binding cassette A7 (ABCA7) gene is a key genetic factor identified in late-onset Alzheimer's disease (LOAD) via genome-wide association studies (GWASs).
- ABCA7, a transmembrane protein in the ATP-binding cassette transporter superfamily, is highly expressed in brain microglial cells.
- Elevated ABCA7 levels in Alzheimer's disease (AD) brains correlate positively with amyloid plaque burden and disease severity.
Purpose of the Study:
- To review the known functions of the ABCA7 gene and its association with Alzheimer's disease pathogenesis.
- To discuss single-nucleotide polymorphisms (SNPs) in ABCA7 linked to LOAD and their potential physiological impacts.
- To explore the therapeutic potential of targeting ABCA7 for Alzheimer's disease treatment.
Main Methods:
- Literature review of studies investigating ABCA7's role in Alzheimer's disease.
- Analysis of genome-wide association studies (GWASs) identifying ABCA7 as a LOAD risk locus.
- Examination of research on ABCA7 expression, function, and its relationship with AD pathology markers.
Main Results:
- ABCA7 is strongly associated with LOAD, with increased expression in AD brains.
- ABCA7 may influence AD pathogenesis through pathways including amyloid-beta (Aβ) accumulation, lipid metabolism, and phagocytosis.
- Specific single-nucleotide polymorphisms (SNPs) in ABCA7 are linked to increased LOAD risk.
Conclusions:
- ABCA7 plays a significant role in Alzheimer's disease development and progression.
- Understanding ABCA7's functions and associated genetic variations is crucial for AD research.
- Targeting ABCA7 presents a promising novel therapeutic strategy for Alzheimer's disease.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
32
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
32
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:29Alzheimer Disease l: Introduction
20
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
20
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:22Dementia l: Introduction
31
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
31